Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07409246 | A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) | recruiting | Phase 1 | 127 | AbbVieINDUSTRY | 4 | Sep 29, 2026 | clinicaltrials |
| NCT04973605 | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 246 | BeOne MedicinesINDUSTRY | 13 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT07660939 | GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders | recruiting | Phase 1 | 50 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06768489 | A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma | recruiting | Phase 1 | 276 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT07336472 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 360 | Fortvita Biologics (USA)Inc.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07116616 | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 190 | ModernaTX, Inc.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06465316 | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03909412 | Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma(CarMob) | recruiting | Phase 1 | 18 | Hackensack Meridian HealthOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07802717 | A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 40 | Vyriad, Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07210047 | Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 21 | HuniLife Biotechnology, Inc.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04879043 | Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 78 | Heidelberg Pharma AGINDUSTRY | 5 | Sep 17, 2026 | clinicaltrials |
| NCT04910568 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma(CAMMA 1) | recruiting | Phase 1 | 186 | Genentech, Inc.INDUSTRY | 13 | Sep 17, 2026 | clinicaltrials |
| NCT07760454 | A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 68 | UCARsgen Biotech LimitedOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05892393 | Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma | recruiting | Phase 1 | 20 | Robert Flavell, MD, PhDOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07181941 | Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07620275 | Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA | recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06953960 | A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 325 | AbbVieINDUSTRY | 12 | Sep 14, 2026 | clinicaltrials |
| NCT07558915 | A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | recruiting | Phase 1 | 160 | Genentech, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06049290 | A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 342 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07455851 | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 150 | Regeneron PharmaceuticalsINDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT05583617 | A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma(PLYCOM) | recruiting | Phase 1 / Phase 2 | 200 | Hoffmann-La RocheINDUSTRY | 6 | Sep 3, 2026 | clinicaltrials |
| NCT05927571 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 | 120 | Genentech, Inc.INDUSTRY | 3 | Sep 3, 2026 | clinicaltrials |
| NCT07479979 | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 62 | Natalie CallanderOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06375044 | Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 130 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 2 | Aug 28, 2026 | clinicaltrials |
| NCT07075185 | A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma(inMMyCAR) | recruiting | Phase 1 | 70 | Kelonia Therapeutics, Inc.INDUSTRY | 2 | Aug 28, 2026 | clinicaltrials |
| NCT05836896 | A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies(CARLOTTA01) | recruiting | Phase 1 | 16 | Technische Universität DresdenOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07681596 | A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 101 | AstraZenecaINDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT06087653 | Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 24 | Starton Therapeutics, IncINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06066359 | Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma | recruiting | Phase 1 / Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments(DynaMMic-1) | recruiting | Phase 1 / Phase 2 | 123 | GlaxoSmithKlineINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT06106945 | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 226 | AstraZenecaINDUSTRY | 9 | Aug 19, 2026 | clinicaltrials |
| NCT05651932 | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | recruiting | Phase 1 | 165 | K36 Therapeutics, Inc.INDUSTRY | 4 | Aug 18, 2026 | clinicaltrials |
| NCT05850234 | AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)(DURGA-1) | recruiting | Phase 1 / Phase 2 | 232 | AstraZenecaINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07105059 | A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07341867 | Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype | recruiting | Phase 1 | 90 | Andrew Hantel, MDOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06622005 | SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07463807 | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment | recruiting | Phase 1 / Phase 2 | 162 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07280013 | A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | recruiting | Phase 1 | 60 | C4 Therapeutics, Inc.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05887167 | Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies | recruiting | Phase 1 | 20 | Joshua Sasine, MD, PhDOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05976555 | Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma | recruiting | Phase 1 | 30 | Medical College of WisconsinOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06105554 | Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05092451 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05632380 | ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06669247 | A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma(COSTIMM) | recruiting | Phase 1 / Phase 2 | 186 | Regeneron PharmaceuticalsINDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07652281 | A Clinical Study of SHR-5421 in Patients With Multiple Myeloma | recruiting | Phase 1 | 97 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07099391 | A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
Data updated 14 hours agoSource updated Sep 29, 2026source: clinicaltrials